Postepy Dermatol Alergol. 2013 Oct;30(5):286-92. doi: 10.5114/pdia.2013.38357. Epub 2013 Oct 30.

Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus.

Postepy dermatologii i alergologii

Ewa Teresiak-Mikołajczak, Magdalena Czarnecka-Operacz, Dorota Jenerowicz, Wojciech Silny

PMID: 24353488 PMCID: PMC3858656 DOI: 10.5114/pdia.2013.38357

Abstract

INTRODUCTION: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease, characterized by eczematous skin lesions and intensive pruritus. Recent studies have shed light on the role of the nervous system in the pathogenesis of AD. It can influence the course of the disease through an altered pattern of cutaneous innervation and abnormal expression of neuropeptides in the lesional skin.

AIM: The aim of the study was to evaluate plasma concentrations of the nerve growth factor (NGF), substance P (SP) and vasoactive intestinal peptide (VIP) in AD patients in comparison to two control groups (healthy volunteers and patients suffering from psoriasis). Correlations between plasma levels of evaluated parameters, severity of the disease and selected clinical parameters (skin prick tests, total and antigen specific IgE levels) were also analysed.

MATERIAL AND METHODS: Seventy-five patients with AD, 40 patients with psoriasis and 40 healthy volunteers were included into the study. Patients with AD included 52 persons suffering from an extrinsic and 23 from an intrinsic type of the disease. The severity of skin lesions was assessed with SCORAD index. Pruritus was evaluated on the basis of the questionnaire assessing the extent, frequency and intensity of pruritus. Commercial enzyme-linked immunosorbent assays (SP, NGF: R&D Systems; and VIP: Phoenix Pharmaceuticals) were used to assess the neuropeptide and NGF plasma levels.

RESULTS: Nerve growth factor and VIP plasma concentrations were significantly higher in AD patients compared to psoriatic patients and healthy subjects. Substance P plasma concentrations were elevated in the extrinsic type of AD and psoriasis comparing to healthy volunteers. There were no statistically significant differences in NGF, SP and VIP plasma concentrations between the extrinsic and intrinsic type of AD. There was also no correlation between plasma levels of evaluated parameters (NGF, SP, VIP) and SCORAD index in both types of AD. However, plasma SP concentration correlated with intensity of pruritus in AD patients. Plasma VIP concentrations correlated with intensity of pruritus in the intrinsic type of AD and with IgE-mediated sensitization to moulds in the extrinsic type of disease.

CONCLUSIONS: Our findings confirm that NGF and VIP play a prominent role in atopic inflammatory reactions and may serve as good alternative biomarkers of AD. The results of this study also suggest a similar important role of neuroimmune interactions in both variants of AD. Increased SP plasma concentrations in both AD and psoriasis point to its possible role in modulating immune-mediated inflammation in different chronic inflammatory skin diseases. Moreover, SP and VIP seem to influence the course of AD by increasing pruritus, whereas an elevated plasma VIP level in AD patients may be related to a risk of developing IgE-mediated sensitization to certain airborne allergens.

Keywords: atopic dermatitis; extrinsic type; intrinsic type; neuropeptides

References

1. Exp Dermatol. 1992 Oct;1(3):127-8 - PubMed
2. J Allergy Clin Immunol. 1992 Oct;90(4 Pt 1):613-22 - PubMed
3. Exp Dermatol. 2002 Feb;11(1):12-24 - PubMed
4. J Dermatol Sci. 2009 Jan;53(1):48-54 - PubMed
5. Br J Dermatol. 1989 Dec;121(6):681-8 - PubMed
6. Neuropeptides. 2011 Dec;45(6):417-22 - PubMed
7. Respir Res. 2001;2(3):133-8 - PubMed
8. J Dermatol Sci. 2012 Apr;66(1):37-43 - PubMed
9. Arch Dermatol Res. 1997 Feb;289(3):125-31 - PubMed
10. J Immunol. 2003 Jan 1;170(1):308-14 - PubMed
11. J Dermatol Sci. 2003 Apr;31(2):161-4 - PubMed
12. J Eur Acad Dermatol Venereol. 2008 Feb;22(2):223-8 - PubMed
13. Allergy. 2001 Sep;56(9):813-24 - PubMed
14. Acta Derm Venereol. 2010 Nov;90(6):582-8 - PubMed
15. Acta Derm Venereol Suppl (Stockh). 1992;176:90-2 - PubMed
16. J Clin Invest. 2004 Mar;113(5):651-7 - PubMed
17. Int Arch Allergy Immunol. 2007;144(3):211-6 - PubMed
18. Br J Dermatol. 2002 Jul;147(1):71-9 - PubMed
19. Allergy. 2006 Dec;61(12):1416-8 - PubMed
20. J Dermatol Sci. 2006 Apr;42(1):47-54 - PubMed
21. Arch Dermatol Res. 2006 Jun;298(1):31-7 - PubMed
22. J Invest Dermatol. 2011 Mar;131(3):735-43 - PubMed
23. Eur J Clin Invest. 2003 Jun;33(6):513-7 - PubMed
24. Allergy Asthma Immunol Res. 2010 Oct;2(4):235-46 - PubMed
25. J Infect Dis. 2011 Mar 15;203(6):862-9 - PubMed
26. Br J Dermatol. 1990 Jun;122(6):745-50 - PubMed
27. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10440-4 - PubMed
28. J Biomed Biotechnol. 2011;2011:790436 - PubMed
29. Clin Exp Allergy. 2008 Aug;38(8):1302-8 - PubMed
30. Clin Exp Allergy. 2006 Nov;36(11):1408-16 - PubMed
31. J Cell Physiol. 2004 Nov;201(2):167-80 - PubMed
32. J Dermatol Sci. 2012 Jul;67(1):37-43 - PubMed
33. J Immunol. 2001 Mar 1;166(5):2907-12 - PubMed
34. Acta Derm Venereol Suppl (Stockh). 1992;176:93-4 - PubMed
35. Arch Dermatol Res. 2007 Sep;299(7):345-51 - PubMed
36. J Allergy Clin Immunol. 2006 Mar;117(3):583-9 - PubMed
37. Clin Exp Allergy. 2003 Dec;33(12):1618-21 - PubMed

Publication Types

• Journal Article